Yuhan and Jansen Will Transfer Won 1400 Billion Lung Cancer Drugs | Computer Science

The inhibitor of EGFR TKI,
Technology transfer to global pharmaceutical company Janse Biotech, a subsidiary of J & J
Deposit of 56 billion won, step by step of 1.35 trillion won
Global clinical progress next year

Yuhan Central Research Institute

Yuhan Corporation178,0009,000 5.33%) Successfully transferred a large-scale technology of 1,400 billion won.

Yuhan has announced the signing of a technology export contract with Janssen Biotech, a subsidiary of the global pharmaceutical group Johnson & Johnson (J & J), for the EGFR TKI & # 39; LaserTip & # 39; # 39; (project name YH25448). The total amount of the contract is approximately 1,400 billion won ($ 1,255 million), which represents only W $ 56 billion (US $ 50 million) with no restitution obligation.

Under the terms of this agreement, Jansen will have the exclusive rights to develop, manufacture and market LaserTinib worldwide. The right of development and marketing in Korea is maintained by Yuhan. Yuhan will work with Jansen Biotech on global clinical trials of monotherapy and combined therapies with LaserTinib starting next year.

Yuhan expects to receive a total of $ 1.25 trillion (about 1.35 trillion won) for development, licensing and sales milestone technology costs. This is the joint development of Yuhan Corp. Oscotech (25,7501,850 7.74%) And 40% of the amount of technology exports and ordinary technical expenses paid to Genosco will be distributed. When the product is marketed, it receives royalties corresponding to net sales. If clinical trials, licenses and marketing fail, the technology transfer agreement is terminated and Yuhan will not pay any fine to Janssen.

Lasertinib is a tolerable lung cancer drug candidate that selectively inhibits the mutation of EGFR. The EGFR TK Inhibitor (EGFR) is a selective third-generation EGFR inhibitor that is selective and irreversible and permeates brain tissue. It is a potent drug for non-small cell lung cancer EGFR TK-mutant Respectively. Since last July, Yuhan and Genosko have jointly sponsored a Phase I clinical trial in non-small cell lung cancer in Korea.

Preliminary clinical results indicate that lasatinib is effective in patients with non-small cell lung cancer and resistant to TK-EGFR inhibitors, whether or not they have brain metastases. The incidence of serious adverse events was higher than that of the third level. It is more effective than competing medicines and has excellent safety. The company expects it to be a success in the development of a combination therapy.

Janghee Lee, CEO of Yonsei University, said: "Given Jansen's excellent scientific expertise in lung cancer and cancer research and development, Jansen is the best strategic partner. " Through the collaboration between the two companies, I will make efforts to advance the development of.

Jeon Ye Jin reporter [email protected]